HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lawyers Urge Firms To Be Ready For Nanotech Torts, Tougher Inspections

This article was originally published in The Rose Sheet

Executive Summary

Manufacturers of nanotechnology-based products should be on guard for lawsuits filed by employees and an anxious plaintiffs' bar, as well as increased attention from regulatory officials under the new administration, according to lawyers

You may also be interested in...



Omnibus Funding Bill Includes $1 Mil. Boost For FDA’s Cosmetics Office

Members of Congress want detailed quarterly updates from FDA on how the agency uses its 2009 appropriation, which includes a $1 million increase for the Office of Cosmetics and Colors, according to a joint explanatory statement accompanying the omnibus spending bill

Omnibus Funding Bill Includes $1 Mil. Boost For FDA’s Cosmetics Office

Members of Congress want detailed quarterly updates from FDA on how the agency uses its 2009 appropriation, which includes a $1 million increase for the Office of Cosmetics and Colors, according to a joint explanatory statement accompanying the omnibus spending bill

Obama Wants FDA’s “Full Review” As Recall Of Peanut Butter Items Goes On

FDA is due for a "full review" in light of a salmonella outbreak that has sickened more than 500 people, possibly killed eight, and prompted a massive recall of peanut butter products, according to President Obama

Latest Headlines
See All
UsernamePublicRestriction

Register

RS015980

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel